145589-03-3

Basic information

• Product Name: (R)-3-(3-Methylbutanoyl)-4-benzyloxazolidin-2-one
• Synonyms: (R)-3-(3-methylbutanoyl)-4-benzyloxazolidin-2-one;Oxazolidinone, 3-(3-methyl-1-oxobutyl)-4-(phenylmethyl)-, (4R)-;3-isovaleroyl-4(R)-benzyl-oxazolidin-2-one;(4R)-4-benzyl-3-(3-Methylbutanoyl)-1,3-oxazolidin-2-one;3-(3-Methyl-1-oxobutyl)-4-(p henylMethyl)-, (R)-2-Oxazolidinone;(4R)-3-(3-Methyl-1-oxobutyl)-4-(phenylMethyl)-2-oxazolidinone;(4R)-4-Benzyl-3-isovaleryloxazolidin-2-one;4R-Benzyl-3-(3-Methylbutyryl)oxazolidin-2-one
• CAS NO: 145589-03-3
• Molecular Formula: C₁₅H₁₉NO₃
• Molecular Weight: 261.31626
• Product Categories: Aromatics;Chiral Reagents;Miscellaneous Reagents
• Mol File: 145589-03-3.mol
• Article Data: 32

Chemical Properties

• Boiling Point: 412.912 °C at 760 mmHg
• Flash Point: 203.522 °C
• Appearance: White solid
• Density: 1.152
• Vapor Pressure: 5E-07mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• PKA: -2.33±0.40(Predicted)
• CAS DataBase Reference: (R)-3-(3-Methylbutanoyl)-4-benzyloxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(3-Methylbutanoyl)-4-benzyloxazolidin-2-one(145589-03-3)
• EPA Substance Registry System: (R)-3-(3-Methylbutanoyl)-4-benzyloxazolidin-2-one(145589-03-3)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 145589-03-3(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

(R)-3-(3-Methylbutanoyl)-4-benzyloxazolidin-2-one (cas# 145589-03-3) is a compound useful in organic synthesis.

InChI:InChI=1/C15H19NO3/c1-11(2)8-14(17)16-13(10-19-15(16)18)9-12-6-4-3-5-7-12/h3-7,11,13H,8-10H2,1-2H3/t13-/m1/s1

Upstream product

• 108-12-3 isopentanoyl chloride 
• 503-74-2 3-methylbutyric acid 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 63-91-2 L-phenylalanine 
• 134807-37-7 (4S)-3-((2S)-4-(tert-butoxy)-2-(1-methylethyl)-4-oxobutanoyl)-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 100-51-6 benzyl alcohol 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 90719-30-5 (4S)-3-((E)-2-butenoyl)-4-benzyl-2-oxazolidinone 
• 1184-58-3 dimethylaluminum chloride 

Downstream Products

• 156546-62-2 (S)-4-Benzyl-3-((S)-3-methyl-2-phenylsulfanyl-butyryl)-oxazolidin-2-one 
• 173336-02-2 2(R)-isopropyl-3-(3-hydroxy-4-tert-butyl-phenyl)-propanol 
• 365541-74-8 (4R)-3-{(2S)-3-methyl-1-oxo-2-[(phenylmethoxy)methyl]butyl}-4-(phenylmethyl)oxazolidin-2-one 
• 150615-46-6 (S)-4-benzyl-3-[(R)-2-hydroxymethyl-3-methylbutanoyl]oxazolidinone 
• 172900-72-0 (4R)-3-{(2R)-2-{[4-methoxy-3-(methoxypropoxy)phenyl]methyl-3-methyl}-1-oxobutyl}-4-(phenylmethyl)oxazolidin-2-one 
• 919995-31-6 trans-1-bromo-6-[4-(S)-benzyl-2-oxo-oxazolidin-3-yl]-(S)-isopropyl-hex-2-en-6-one 
• 919995-32-7 trans-1-[4-(S)-benzyl-2-oxo-oxazolidin-3-yl]-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-2(S)-7(S)-diisopropyl-oct-4-en-1,8-dione 
• 324519-70-2 C₁₈H₂₂ClNO₃ 
• 172900-81-1 3-[2(R)-isopropyl-3-(p-tert-butyl-phenyl)-propanoyl]-4(R)-benzyl-oxazolidin-2-one 
• 173400-44-7 4(R)-benzyl-3-{2(S)-isopropyl-3-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-propionyl}-oxazolidin-2-one 
• 324519-70-2 C₁₈H₂₂ClNO₃ 
• 953820-21-8 (R)-4-benzyl-3-((R)-2-((1-(3-methoxypropyl)-1H-indazol-6-yl)methyl)-3-methylbutanoyl)-oxazolidin-2-one 
• 1413429-42-1 (3S,5S)-dihydro-5-{(1S,3S)-1-hydroxy-3-[4-methoxy-3-(3-methoxypropoxy)benzoyl]-4-methylpentyl}-3-(1-methylethyl)furan-2(3H)-one 
• 393108-57-1 (3S,5S)-5-{(1R,3S)-1-bromo-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one 

Relevant articles and documents

An improved and economical process for the manufacture of the key intermediate of aliskiren, a new potent renin inhibitor

An improved, practical, economical and efficient process for the production of (2S,4S)-2-amino-4-(4-methoxy-3-(3-methoxypropoxy)benzyl)-5-methylhexanoic acid, a key intermediate of the new potent renin inhibitor of aliskiren, in a total yield over 30% is described. This process avoids expensive reagents and chromatographic purifications, and is easily scaled up in industry.

JAK INHIBITORS

Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

JAK INHIBITORS

Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.